recombinant

(redirected from Teriparatide)
Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.

re·com·bi·nant

(rē-kŏm′bə-nənt)

1. An organism, cell, or virus in which genetic recombination has taken place.

2. Material produced by genetic engineering.

adj.

1. Formed by or showing recombination: a recombinant chromosome.

2. Of or relating to recombinant DNA: recombinant fragments; recombinant technology.

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

recombinant

(riːˈkɒmbɪnənt) genetics

adj

(Genetics) produced by the combining of genetic material from more than one origin

(Genetics) a chromosome, cell, organism, etc, the genetic makeup of which results from recombination

Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014

re•com•bi•nant

(riˈkɒm bə nənt)
adj.

1. of or resulting from new combinations of genetic material: recombinant cells.

2. a cell or organism whose genetic material results from recombination.

3. the genetic material produced when segments of DNA from different sources are joined to produce recombinant DNA.

[1940–45]

ThesaurusAntonymsRelated WordsSynonymsLegend:

Switch to new thesaurus

Noun	1.	recombinant - a cell or organism in which genetic recombination has occurred organism, being - a living thing that has (or can develop) the ability to act or function independently cell - (biology) the basic structural and functional unit of all organisms; they may exist as independent units of life (as in monads) or may form colonies or tissues as in higher plants and animals
Adj.	1.	recombinant - of or relating to recombinant DNA

Translations

recombiné

recombinant

adj recombinante

References in periodicals archive ?

Budapest, Hungary-based Gedeon Richter Plc announced today that it has introduced its biosimilar teriparatide, Terrosa in Europe.

Gedeon Richter launches Terrosa in Europe

Global Banking News-August 20, 2019-Richter unveils biosimilar teriparatide Terrosa across European osteoporosis market

Richter unveils biosimilar teriparatide Terrosa across European osteoporosis market

M2 EQUITYBITES-August 20, 2019-Richter unveils biosimilar teriparatide Terrosa across European osteoporosis market

Richter unveils biosimilar teriparatide Terrosa across European osteoporosis market

Although teriparatide, a recombinant human PTH (1-34), is widely used in the treatment of osteoporosis, there is a limited number of literature data on its use for hypoparathyroidism.

Alternative treatment of resistant hypoparathyroidism by intermittent infusion of teriparatide using an insulin pump: A case report

The first anabolic drug to be approved by the FDA for osteoporosis, teriparatide (Forteo, Lilly), increases BMD while lowering the risk of fractures.

Bone-Building Meds Battle Osteoporosis: These drugs stimulate new bone growth, making them powerful weapons against advanced osteoporosis

###- Skills developed for insulin motivation may be utilized to enhance adherence to teriparatide, denosumab therapy.

Osteovigilance in diabetes

Parathyroid Hormone (PTH) and its analogue Teriparatide (TPD) provide the possibility of improving skeletal microarchitecture and represent a new class of anabolic therapies for the treatment of severe osteoporosis (3).

A Feasibility Study to Evaluate Bacillus subtilisas a Host for Producing Recombinant Human Parathyroid Hormone

Pfenex (PFNX) and Alvogen announced entering into an agreement granting Alvogen exclusive rights to commercialize Pfenex's lead drug candidate, PF708, a teriparatide therapeutic equivalent candidate to Eli Lilly's (LLY) Forteo, in the United States.

Pfenex announces commercialization agreement for PF708 with Alvogen

Two of these peptide hormone medications are abaloparatide (brand name Tymlos) and teriparatide (brand name Forteo).

Osteoporosis: Making Sense of a Diagnosis and Tough Decisions About Treatment

Teriparatide was used in 41.2% (7 patients) with AFF and in 18.2% (2 patients) with osteoporotic femoral fractures (p = 0.25).

Comparison of Atypical and Osteoporotic Femoral Shaft Fractures in the Elderly: A Multicenter Study

DENVER--A treatment regimen for postmenopausal women with osteoporosis that started with teriparatide for 2 years and switched to denosumab improved their spine trabecular microarchitecture--a predictor of fracture risk independent of areal bone mineral density--in a new analysis of the DATA trial and its extension study, DATA-Switch.